Navigation Links
Clinical Trial by Licensee Does Not Meet Primary Endpoint
Date:7/30/2009

PASADENA, Calif., July 30 /PRNewswire-FirstCall/ -- AutoImmune Inc. (OTC Bulletin Board: AIMM) today announced its licensee, BioMS Medical Corp., and Eli Lilly and Company reported that dirucotide did not meet the primary endpoint of delaying disease progression, as measured by the Expanded Disability Status Scale (EDSS), during the two-year Phase III trial in patients with secondary progressive multiple sclerosis (SPMS). In addition, there were no statistically significant differences between dirucotide and placebo on the secondary endpoints of the study. Lilly and BioMS also announced that they would discontinue ongoing clinical trials and review available data.

AutoImmune has exclusively licensed certain of its intellectual property rights to BioMS. Under the license agreement, BioMS makes monthly diligence payments to AutoImmune and will pay royalties to AutoImmune on sales of its lead drug, dirucotide, if it reaches the market.

Chairman of the Board and Chief Executive Officer Robert C. Bishop, Ph.D. stated, "We are obviously disappointed by the results and look forward to further announcements from BioMS and Lilly regarding their future plans for this approach to treating SPMS."

AutoImmune is a biopharmaceutical company involved in the development of treatments for autoimmune and cell-mediated inflammatory diseases and conditions.

Statements in this release that are not strictly historical are forward-looking statements including statements about clinical trials and studies and future sales, royalties and revenue. You can identify these forward-looking statements because they involve our expectations, beliefs, projections, anticipations or other characterizations of future events or circumstances. These forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties that may cause actual results to differ materially from those in the forward-looking statements as a result of any number of factors. These factors include, but are not limited to, the uncertainties of clinical trial results, AutoImmune's dependence on third parties for licensing revenue, and the risks of technological change and competition. These factors are more fully discussed, as are other factors, in AutoImmune's most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission in the section entitled "Risk Factors."


'/>"/>
SOURCE AutoImmune Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Are imaging features of hepatic angiomyolipoma related to its clinical setting?
2. Summa Health System Creates Quick Win With Their Caregiver Community By Implementing Sentillions Clinical Workstation Solution
3. ULURU Inc. to Present Altrazeal(TM) Clinical Evidence at the American Podiatric Medical Association (APMA) Annual Scientific Meeting in Toronto, Canada
4. HOWARU(R) Protect Clinically Shown to Reduce the Incidence and Severity of Cold and Flu Symptoms in Children
5. Sunshine Heart Provides C-Pulse U.S. Clinical Update
6. QLT announces interim data from a Phase II clinical trial and a device study for the Punctal Plug Drug Delivery System
7. Lexicon Pharmaceuticals Provides Clinical Pipeline Update and Reports 2009 Second Quarter Financial Results
8. Alexza to Announce 2009 Second Quarter Financial Results and Update Its Clinical Pipeline Status on Wednesday, August 5, 2009
9. Male Fertility Supplement Improves Sperm Quality & Motility in Clinical Study
10. Lutonix, Inc. Announces First Patient Enrollments in Three Separate Clinical Trials
11. Cardiorobotics Closes $11.6M Series A Financing to Advance Clinical Development of Snake Robot for Surgery
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... Head Island, SC (PRWEB) , ... February 08, 2016 , ... ... and surrounding areas with a vital new community enrichment program, has teamed up with ... local women and children suffering from intimate abuse. To support all those victimized by ...
(Date:2/8/2016)... , ... February 08, 2016 , ... Remember the old ... , According to Perry A~, author of “Calcium Bentonite Clay” the health benefits ... role in balancing and detoxifying the body. , A former motivational speaker, Perry A~ ...
(Date:2/8/2016)... ... February 08, 2016 , ... ... share this important news! AHCC and the Home Health and Hospice ICD-10 Transition ... designee for official ICD coding guidance and clarifications, to address concerns over the ...
(Date:2/8/2016)... ... , ... According to research by the National Association of ... be certified or obtain continuing education. To increase patient awareness of the lack ... campaign to inform dentists and patients about the possible lack of skills and ...
(Date:2/6/2016)... , ... February 06, 2016 ... ... 303-368-6225 , MEDIA ADVISORY: 5000 PERIOPERATIVE NURSES EXPECTED AT AORN SURGICAL CONFERENCE ... perioperative nurses in the world with an estimated 5000 perioperative nurses in ...
Breaking Medicine News(10 mins):
(Date:2/8/2016)... , February 8, 2016 ... market research report "Ablation Technologies Market by Product (Radiofrequency, ... Pain Management, Cosmetic Surgery, Ophthalmology, Gynecology) - Global Forecasts ... global market over the forecast period of 2015 to ... by 2020, at CAGR of 10.5% from 2015 to ...
(Date:2/8/2016)... NORRITON, Pa. , Feb. 8, 2016 /PRNewswire/ ... of November Research Group (NRG),s pharmacovigilance technology ... pharmacovigilance system-related consulting services and an Oracle Argus ... compliance services to Life Sciences companies. ... strengthens and expands HighPoint,s life sciences capabilities and ...
(Date:2/8/2016)... part of a major growth and expansion initiative, Dune Medical ... Chmura as President of Dune Inc., its U.S. division. ... experience in the medical device space will play a large ... --> --> In her new ... and operational functions in the U.S. She is tasked with ...
Breaking Medicine Technology: